Condition (MeSH)
Hyperlipoproteinemia Type V
ClinicalTrials.gov lists 6 trials for Hyperlipoproteinemia Type V or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
6 of the 6 trials are tagged with Hyperlipoproteinemia Type V itself; the rest are tagged with a narrower condition beneath it.
When did Hyperlipoproteinemia Type V trials start? (4)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- Not applicable
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2021 | 3 |
| 2007 | 1 |
| 2006 | 1 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 6 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hyperlipoproteinemia Type V trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
| Not applicable | 1 |
How many Hyperlipoproteinemia Type V trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Active, not recruiting | 1 |
| Completed | 2 |
| Terminated | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hyperlipoproteinemia Type V trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| AstraZeneca | 1 |
| CRISPR Therapeutics AG | 1 |
| Jiangsu HengRui Medicine Co., Ltd. | 1 |
| Korea United Pharm. Inc. | 1 |
| Merck Sharp & Dohme LLC | 1 |
Which serious adverse events do Hyperlipoproteinemia Type V trials report? (1)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Femur And Rotula Right Fracture That Required Hospitalization | 1 | 1 |
Which publications cover Hyperlipoproteinemia Type V? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. | Cardiovascular diabetology | 2017 | Yes |
| Quantification of human plasma apolipoproteins C-I, C-II, and C-III by radioimmunoassays. | Mayo Clinic proceedings | 1993 | No |
| Predictors of total and low-density lipoprotein cholesterol change after partial ileal bypass. | American journal of surgery | 1988 | No |
| Pathogenesis and management of lipoprotein disorders. | The New England journal of medicine | 1985 | No |
| Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia. | The New England journal of medicine | 1985 | No |
Showing 5 of 7 publications.
Prevalence (2)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Familial apolipoprotein A5 deficiency | Cases families | Worldwide | Not stated | Unspecified | |
| Familial apolipoprotein A5 deficiency | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Unspecified |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: rare-disease identity and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.